ClinicalTrials.gg
CompletedNCT05974267Updated Feb 6, 2026Results posted

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

A Phase 2 interventional study of M5717 60 mg and Pyronaridine in Malaria Infection, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 4 sites in 4 countries. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
12 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies in Malaria, Falciparum with a site in Burkina Faso — 6 open to participants now, 11 under way, none of them phase 3. Malaria, Falciparum · Burkina Faso.

Enrollment
29th of 46
192 · median 360
Started
2023
with 3 others
Phase 2
15 of 52
3 open now
Registered
37th of 52
by date
Lead sponsor
2 of 52
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Among the 52 studies in Malaria, Falciparum with a site in Burkina Faso, this one is the 29th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2023, is one of 15 in phase 2, and was the 37th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

6 of the 52 studies in Malaria, Falciparum with a site in Burkina Faso are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Burkina Faso have not opened yet or have stopped. Only those recruiting at a site in Burkina Faso →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 12 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Malaria, Falciparum with a site in Burkina Faso, or all of them as a file.
02

Study summary

This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and adolescents. The study will also assess the duration of protection provided by different doses of M5717 plus pyronaridine and the additional contribution of M5717 to the duration of protection using external study data.

03

Conditions studied

  • Malaria Infection

Keywords

  • Plasmodium falciparum
  • Chemoprevention
  • Malaria
  • Plasmodium eukaryotic translation elongation factor 2 (PeEF2)
  • Exposure response
  • Adults
  • Adolescents
  • Asymptomatic Infection
04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Asymptomatic Plasmodium falciparum Malaria with no Fever or other sign of Acute Uncomplicated Malaria and, with Microscopic confirmation using Giemsa-stained thick film, and a Parasitemia of >= 40 to \<= 10,000 Asexual Parasites/Microliter (μL) of Blood.
  • Axillary Temperature \< 37.0 degree Celcius (ºC) or oral/Tympanic/rectal Temperature\< 37.5ºC; without history of fever during the previous 48 hours.
  • Have a body weight >= 45 kilogram (kg)
  • Participants capable of giving Signed which includes Compliance with the requirements and restriction listed in the Informed consent form
  • Other Protocol defined Inclusion Criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants with any disease requiring Chronic Treatment
  • Participants with any Preplanned surgery during the study
  • Participants with any previous Treatment with pyronaridine as part of a combination therapy during the last 3 months
  • Participants with any adequate Hematological, Hepatic, and renal function as defined in the Protocol
  • Other protocol defined Exclusion Criteria could apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Cohort 1: M5717 (60 mg) + Pyronaridine

    Participants received single oral dose of M5717 60 milligram (mg) plus pyronaridine tetraphosphate (pyronaridine) 720 mg (Participants \>= 65 kilogram \[kg\]) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.

    Drug: M5717 60 mg · Drug: Pyronaridine

  • Experimental
    Cohort 2: M5717 (200 mg) + Pyronaridine

    Participants received single oral dose of M5717 200 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.

    Drug: Pyronaridine · Drug: M5717 200 mg

  • Experimental
    Cohort 3: M5717 (660 mg)+ Pyronaridine

    Participants received single oral dose of M5717 660 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.

    Drug: Pyronaridine · Drug: M5717 660mg

  • Experimental
    Cohort 4: Atovaquone-proguanil

    Participants received orally 3 doses of Malarone (fixed-dose combination of atovaquone-proguanil) once daily in a 3-day treatment regimen.

    Drug: Atovaquone-Proguanil

Interventions

  • Participants received single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition

  • Participants received Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition

    Also known as: Pyronaridine tetraphosphate

  • DrugAtovaquone-Proguanil

    Participants received Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.

  • Participants received single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition

  • Participants received single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition

06

What researchers measure

Primary outcomes

  1. Time to Parasitemia Since Negative Blood Smear After Treatment

    The time (in days) to first recorded parasitemia (parasite count \>0) since the first negative blood smear (parasite count of 0) after treatment (followed at least by 1 subsequent visit with a negative blood film), i.e. the time without a positive blood smear. Median time and 95% CI was estimated using the Kaplan Meier method for each cohort.

    Time frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)

Secondary outcomes

  1. Percentage of Participants With Parasitemia (Positive Blood Smear)

    Percentage of participants with a positive blood smear (parasitemia) was reported. Parasitemia is the presence of parasites in blood (parasite count \>0).

    Time frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)

  2. Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Parasitemia (Due to New Infections)

    Percentage of participants with polymerase chain reaction (PCR)-adjusted Parasitemia (Thick Smear/Microscopy, after Adjustment for Parasitemia due to new Infections as determined by Genotyping using PCR Techniques) was reported.

    Time frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)

  3. Percentage of Participants With PCR-adjusted Parasitemia (Due to Recrudescence)

    Percentage of participants with polymerase chain reaction (PCR)-adjusted Parasitemia (Thick Smear/Microscopy, after Adjustment for Parasitemia due to Recrudescence as determined by Genotyping using PCR Techniques) was reported.

    Time frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)

  4. Parasite Clearance Time

    Parasite clearance time defined as time from dosing to the first negative (no parasites) blood film (microscopy). Median parasite clearance time was estimated by Kaplan-Meier method

    Time frame: Time from dosing to the first negative (no parasites) blood film (microscopy) , assessed up to 12 weeks

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs and Treatment Related TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE was defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Treatment-related TEAEs: reasonably related to study intervention.

    Time frame: Up to End of Study (approximately 12 Weeks)

  6. Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717 and Pyronaridine

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated blood concentration at the last sampling time point at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured blood concentrations of the terminal log-linear phase.

    Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2

  7. Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717 and Pyronaridine

    AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

    Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2

  8. Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717 and Pyronaridine

    Area under the blood concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2

  9. Apparent Total Body Clearance From Blood (CL/f) of M5717 and Pyronaridine

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from blood, CL= Dose/AUC0-inf.

    Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2

  10. Maximum Observed Blood Concentration (Cmax) of M5717 and Pyronaridine

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2

  11. Apparent Terminal Half-life (t1/2) of M5717 and Pyronaridine

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

    Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2

  12. Time to Reach the Maximum Blood Concentration (Tmax) of M5717 and Pyronaridine

    Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2

  13. Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717 and Pyronaridine

    The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z). Vz/f=Dose/AUC(0-inf) multiply Lambda(z).

    Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2

07

Results

Posted Feb 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanil
Started49474848
Completed29273232
Not completed20201616
Withdrew: Lack of efficacy19191515
Withdrew: Other: the parent of the participant who is a minor, withdrew the participant from the trial1000
Withdrew: Protocol deviation0100
Withdrew: Withdrawal by subject0011

Outcome measures

PrimaryTime to Parasitemia Since Negative Blood Smear After Treatment

The time (in days) to first recorded parasitemia (parasite count \>0) since the first negative blood smear (parasite count of 0) after treatment (followed at least by 1 subsequent visit with a negative blood film), i.e. the time without a positive blood smear. Median time and 95% CI was estimated using the Kaplan Meier method for each cohort.

Time frame:
From treatment Day 1 up to End of observation period Day 64 (Week 10)
Reported as:
Median · days
Time to Parasitemia Since Negative Blood Smear After Treatment
daysCohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanil
Time to Parasitemia Since Negative Blood Smear After Treatment62.0 (49.0 to 100.0)60.0 (47.0 to 100.0)NA (61.0 to 100.0)NA (59.0 to 100.0)
SecondaryPercentage of Participants With Parasitemia (Positive Blood Smear)

Percentage of participants with a positive blood smear (parasitemia) was reported. Parasitemia is the presence of parasites in blood (parasite count \>0).

Time frame:
From treatment Day 1 up to End of observation period Day 64 (Week 10)
Reported as:
Number · percentage of participants
Percentage of Participants With Parasitemia (Positive Blood Smear)
percentage of participantsCohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanil
Percentage of Participants With Parasitemia (Positive Blood Smear)53.151.135.437.5
SecondaryPercentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Parasitemia (Due to New Infections)

Percentage of participants with polymerase chain reaction (PCR)-adjusted Parasitemia (Thick Smear/Microscopy, after Adjustment for Parasitemia due to new Infections as determined by Genotyping using PCR Techniques) was reported.

Time frame:
From treatment Day 1 up to End of observation period Day 64 (Week 10)
Reported as:
Number · percentage of participants
Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Parasitemia (Due to New Infections)
percentage of participantsCohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanil
Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Parasitemia (Due to New Infections)40.836.229.231.3
SecondaryPercentage of Participants With PCR-adjusted Parasitemia (Due to Recrudescence)

Percentage of participants with polymerase chain reaction (PCR)-adjusted Parasitemia (Thick Smear/Microscopy, after Adjustment for Parasitemia due to Recrudescence as determined by Genotyping using PCR Techniques) was reported.

Time frame:
From treatment Day 1 up to End of observation period Day 64 (Week 10)
Reported as:
Number · percentage of participants
Percentage of Participants With PCR-adjusted Parasitemia (Due to Recrudescence)
percentage of participantsCohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanil
Percentage of Participants With PCR-adjusted Parasitemia (Due to Recrudescence)4.112.84.24.2
SecondaryParasite Clearance Time

Parasite clearance time defined as time from dosing to the first negative (no parasites) blood film (microscopy). Median parasite clearance time was estimated by Kaplan-Meier method

Time frame:
Time from dosing to the first negative (no parasites) blood film (microscopy) , assessed up to 12 weeks
Reported as:
Median · hours
Parasite Clearance Time
hoursCohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanil
Parasite Clearance Time24.1 (6.2 to 39.0)24.2 (12.2 to 39.8)24.0 (12.1 to 48.2)25.0 (24.1 to 48.0)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs and Treatment Related TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE was defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Treatment-related TEAEs: reasonably related to study intervention.

Time frame:
Up to End of Study (approximately 12 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs and Treatment Related TEAEs
ParticipantsCohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanil
Participants with TEAEs31273128
Participants with Serious TEAEs0100
Participants with Treatment-related TEAEs61158
SecondaryArea Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717 and Pyronaridine

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated blood concentration at the last sampling time point at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured blood concentrations of the terminal log-linear phase.

Time frame:
Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Reported as:
Geometric mean · hour*nanogram per milliliter(hour*ng/mL)
Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717 and Pyronaridine
hour*nanogram per milliliter(hour*ng/mL)Cohort 1: M5717 60 mgCohort 2: M5717 200 mgCohort 3: M5717 660 mgCohort 1, 2 and 3: Pyronaridine 540 mgCohort 1, 2 and 3: Pyronaridine 720 mg
Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717 and Pyronaridine613.64 ± 1.12292.02 ± 0.59988.92 ± 0.45985.14 ± 0.56418.17 ± 0.3
SecondaryArea Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717 and Pyronaridine

AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

Time frame:
Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Reported as:
Geometric mean · h*ng/mL
Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717 and Pyronaridine
h*ng/mLM5717 60 mgCohort 2: M5717 200 mgCohort 3: M5717 660 mgCohort 1, 2 and 3: Pyronaridine 540 mgCohort 1, 2 and 3: Pyronaridine 720 mg
Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717 and Pyronaridine205.87 ± 0.4743.74 ± 0.53303.65 ± 0.41594.05 ± 0.61742.89 ± 0.4
SecondaryArea Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717 and Pyronaridine

Area under the blood concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Reported as:
Geometric mean · h*ng/mL
Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717 and Pyronaridine
h*ng/mLCohort 1: M5717 60 mgCohort 2: M5717 200 mgCohort 3: M5717 (660 mg)Cohort 1, 2 and 3: Pyronaridine 540 mgCohort 1, 2 and 3: Pyronaridine 720 mg
Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717 and Pyronaridine455.40 ± 0.52040.41 ± 0.59635.73 ± 0.45393.62 ± 0.65793.71 ± 0.4
SecondaryApparent Total Body Clearance From Blood (CL/f) of M5717 and Pyronaridine

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from blood, CL= Dose/AUC0-inf.

Time frame:
Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Reported as:
Geometric mean · Liter per Hours (L/h)
Apparent Total Body Clearance From Blood (CL/f) of M5717 and Pyronaridine
Liter per Hours (L/h)Cohort 1: M5717 60 mgCohort 2: M5717 200 mgCohort 3: M5717 660 mgCohort 1, 2 and 3: Pyronaridine 540 mgCohort 1, 2 and 3: Pyronaridine 720 mg
Apparent Total Body Clearance From Blood (CL/f) of M5717 and Pyronaridine97.77 ± 1.187.25 ± 0.566.07 ± 0.490.22 ± 0.5112.18 ± 0.3
SecondaryMaximum Observed Blood Concentration (Cmax) of M5717 and Pyronaridine

Cmax was obtained directly from the concentration versus time curve.

Time frame:
Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Blood Concentration (Cmax) of M5717 and Pyronaridine
nanogram per milliliter (ng/mL)Cohort 1: M5717 60 mgCohort 2: M5717 200 mgCohort 3: M5717 660 mgCohort 1, 2 and 3: Pyronaridine 540 mgCohort 1, 2 and 3: Pyronaridine 720 mg
Maximum Observed Blood Concentration (Cmax) of M5717 and Pyronaridine15.19 ± 0.659.69 ± 0.6254.50 ± 0.5157.81 ± 0.6166.46 ± 0.4
SecondaryApparent Terminal Half-life (t1/2) of M5717 and Pyronaridine

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

Time frame:
Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Reported as:
Geometric mean · hour
Apparent Terminal Half-life (t1/2) of M5717 and Pyronaridine
hourCohort 1: M5717 60 mgCohort 2: M5717 200 mgCohort 3: M5717 660 mgCohort 1, 2 and 3: Pyronaridine 540 mgCohort 1, 2 and 3: Pyronaridine 720 mg
Apparent Terminal Half-life (t1/2) of M5717 and Pyronaridine46.013 ± 1.364.663 ± 0.490.234 ± 0.5264.15 ± 0.4246.94 ± 0.6
SecondaryTime to Reach the Maximum Blood Concentration (Tmax) of M5717 and Pyronaridine

Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Reported as:
Median · hour
Time to Reach the Maximum Blood Concentration (Tmax) of M5717 and Pyronaridine
hourCohort 1: M5717 60 mgCohort 2: M5717 200 mgCohort 3: M5717 660 mgCohort 1, 2 and 3: Pyronaridine 540 mgCohort 1, 2 and 3: Pyronaridine 720 mg
Time to Reach the Maximum Blood Concentration (Tmax) of M5717 and Pyronaridine4.067 (1.05 to 141.07)4.00 (1.00 to 12.10)4.00 (1.08 to 175.57)2.10 (1.00 to 7.42)2.08 (1.00 to 12.08)
SecondaryApparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717 and Pyronaridine

The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z). Vz/f=Dose/AUC(0-inf) multiply Lambda(z).

Time frame:
Predose, 1, 2, 4, 6, 8, and 12 hours on Day 1 and 24 hours on Day 2
Reported as:
Geometric mean · liter
Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717 and Pyronaridine
literCohort 1: M5717 60 mgCohort 2: M5717 200 mgCohort 3: M5717 660 mgCohort 1, 2 and 3: Pyronaridine 540 mgCohort 1, 2 and 3: Pyronaridine 720 mg
Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717 and Pyronaridine6490.76 ± 0.58140.36 ± 0.48601.43 ± 0.534383.091 ± 0.539966.70 ± 0.7

Adverse events

Collected over End of Study (approximately 12 Weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: M5717 (60 mg) + Pyronaridine0/49 (0%)0/49 (0%)31/49 (63.3%)
Cohort 2: M5717 (200 mg) + Pyronaridine0/47 (0%)1/47 (2.1%)27/47 (57.4%)
Cohort 3: M5717 (660 mg)+ Pyronaridine0/48 (0%)0/48 (0%)31/48 (64.6%)
Cohort 4: Atovaquone-proguanil0/48 (0%)0/48 (0%)28/48 (58.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanil
Lower limb fractureInjury, poisoning and procedural complications0/491/470/480/48
Most frequent other events
Showing 10 of 77
Most frequent other events
EventCohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanil
MalariaInfections and infestations14/4912/4710/487/48
HeadacheNervous system disorders7/493/476/489/48
Blood alkaline phosphatase increasedInvestigations5/496/473/487/48
Blood bilirubin increasedInvestigations7/494/474/484/48
Aspartate aminotransferase increasedInvestigations3/493/472/485/48
DizzinessNervous system disorders1/492/475/481/48
Upper respiratory tract infectionInfections and infestations3/494/474/482/48
NasopharyngitisInfections and infestations4/492/472/481/48
Urinary tract infectionInfections and infestations2/490/473/483/48
HypercreatininaemiaMetabolism and nutrition disorders3/490/472/483/48

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanilTotal
Mean23 ± 8.624 ± 8.925 ± 9.225 ± 11.225 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanilTotal
Female2016201975
Male29312829117
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: M5717 (60 mg) + PyronaridineCohort 2: M5717 (200 mg) + PyronaridineCohort 3: M5717 (660 mg)+ PyronaridineCohort 4: Atovaquone-proguanilTotal
Ethnicity-Hispanic or Latino12306
Ethnicity-Not Hispanic or Latino48454448185
Ethnicity-Not Reported00101
Race-Black or African American49474848192
08

Study locations

4 sites
  • Groupe de Recherche Action en Sante (GRAS)
    Ouagadougou, Burkina Faso
  • Kisumu County Referral Hospital
    Kisumu, Kenya
  • MRC Unit The Gambia at LSHTM
    Banjul, The Gambia
  • Ndola Teaching Hospital
    Ndola, Zambia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union

Access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.

Data sharing details ↗ · bit.ly

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2024, 13 months.

Results were first posted in Feb 2026, 1 year 1 month after primary completion.

Of 39 phase 2 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 13 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 3, 2023
StartActual
Nov 28, 2023
Primary completionActual
Dec 29, 2024
CompletionActual
Dec 29, 2024
Results first posted
Feb 6, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05974267
Responsible party
Sponsor
First posted
Aug 3, 2023
Start date
Nov 28, 2023
Primary completion
Dec 29, 2024
Completion
Dec 29, 2024
Results posted
Feb 6, 2026
Last update
Feb 6, 2026

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabamiquine · Pyronaridine

Start the discussion